2-Methyl-4-(trifluoromethyl)hexane

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: 2-Methyl-4-(trifluoromethyl)hexane
• 英文别名: 2-methyl-4-(trifluoromethyl)hexane
• 化学式: C₈H₁₅F₃
• 分子量: 168.2
• InChiKey: ZYSPZABPEVECCN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• THREE-DIMENSIONAL CROSSLINKER COMPOSITION AND METHOD OF MANUFACTURING ELECTRONIC DEVICES USING THE SAME
  申请人：ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY

  公开号：US20210397087A1

  公开（公告）日：2021-12-23

  The inventive concept relates to a three-dimensional crosslinker composition and a method of manufacturing an electronic device using the same. According to the inventive concept, the three-dimensional crosslinker composition may be represented by Formula 1 below.

  这个创新概念涉及到一种三维交联剂组合物及其制造电子设备的方法。根据这个创新概念，三维交联剂组合物可以用下面的公式1表示。
• NANOPARTICLE FORMULATION OF BCL-2 INHIBITOR
  申请人：Recurium IP Holdings, LLC

  公开号：US20220273666A1

  公开（公告）日：2022-09-01

  Various albumin nanoparticle Bcl-2 inhibitor formulations are described, along with methods of using them to treat conditions characterized by excessive cellular proliferation, such as cancer and tumors. In various embodiments, such Bcl-2 inhibitor formulations contain albumin and a compound of the following Formula (I), or a pharmaceutically acceptable salt thereof, where the variables in Formula (I) are defined herein.
• US9834710B2
  申请人：——

  公开号：US9834710B2

  公开（公告）日：2017-12-05
• [EN] COMBINATIONS OF BCL-2 INHIBITORS WITH CHEMOTHERAPEUTIC AGENTS<br/>[FR] COMBINAISONS D'INHIBITEURS DE BCL-2 AVEC DES AGENTS CHIMIOTHÉRAPEUTIQUES
  申请人：[en]RECURIUM IP HOLDINGS, LLC

  公开号：WO2022082180A1

  公开（公告）日：2022-04-21

  The present invention relates to the combination of Bcl-2 inhibitor Compound (A) in combination with a chemotherapeutic agent Compound (B) selected from azacitidine, bendamustine, bortezomib, carfilzomib, ixazomib, busulfan, carboplatin, cytarabine, cyclophosphamide, cladribine, cisplatin, capecitabine, decitabine, etoposide, fludarabine, gemcitabine, daunorubicin, doxorubicin, ifosfamide, methotrexate and vincristine, or a pharmaceutically acceptable salt of any of the foregoing, for the treatment of a disease or condition in particular hematological cancers.